A phase Ii trial of Neoadjuvant Ipilimumab follwed by Melphalan (L-PAM) via isolated Limb infusion (ILI) for patients with unresectable In-transit Extremity
Clinical Trial Grant
Administered By
Medicine, Medical Oncology
Awarded By
Bristol-Myers Squibb Company
Start Date
February 1, 2014
End Date
April 2, 2018
Administered By
Medicine, Medical Oncology
Awarded By
Bristol-Myers Squibb Company
Start Date
February 1, 2014
End Date
April 2, 2018